Aussie Court Battle Reveals Progen Offered Pay For Avexa Merger Votes
This article was originally published in PharmAsia News
Progen Pharmaceuticals of Australia apparently offered to pay shareholders for their votes in support of a merger with Avexa, according to information in a federal court case. At issue are conflicting schedules for shareholder meetings to decide on the Progen-Avexa merger. Progen scheduled a March 11 meeting of its shareholders to vote on the proposal, while Cytopia, an Avexa competitor, is in court seeking to delay the meeting until March 27, after it has had a chance to present its own resolution to oust Progen's board. According to court documents, Progen had offered to pay a broker a fee for all proxies that supported the merger. (Click here for more
You may also be interested in...
Europe's largest online pharmacy is calling for online sales of OTC medicines to be allowed in its home market Switzerland, to increase the supply of crucial products to help people manage the symptoms of COVID-19, such as headaches, fever, diarrhoea, coughs, colds or nausea.
Confusion is rife over low UK testing levels to confirm COVID-19 in health care staff and patients, and comparisons with measures taken in similar-sized economies have been unfavorable. Diagnostics manufacturers are not to blame, says the industry.
Novartis's Jakavi joins the likes of Roche's Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients.